Akebia Therapeutics Short Interest Down 21.7% in July (AKBA)
Akebia Therapeutics (NASDAQ:AKBA) saw a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 973,463 shares, a decrease of 21.7% from the July 15th total of 1,242,775 shares, Stock Ratings News reports. Based on an average daily volume of 121,193 shares, the short-interest ratio is presently 8.0 days. Currently, 11.2% of the company’s stock are short sold.
Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at 24.01 on Friday. Akebia Therapeutics has a 52 week low of $16.41 and a 52 week high of $31.00. The stock has a 50-day moving average of $23.94 and a 200-day moving average of $23.66. The company’s market cap is $439.4 million.
Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Monday, August 11th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.34) by $0.05. On average, analysts predict that Akebia Therapeutics will post $-2.04 earnings per share for the current fiscal year.
Akebia Therapeutics Inc is a United States-based biopharmaceutical company, which is focused on the development of small molecules for the treatment of anemia and vascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.